Three new over‑the‑counter continuous glucose monitors—Stelo, Lingo, and Levels—have entered the market, allowing adults to track blood sugar without a prescription or finger‑prick tests. Each device offers distinct features: Stelo focuses on lifestyle impact over a 15‑day wear period, Lingo delivers minute‑by‑minute updates for 14 days, and Levels blends CGM data with biomarker testing for a holistic view of insulin sensitivity.

Stelo’s 15‑Day Wear Time Lets Users Map Food Impacts

According to the source, Stelo is an integrated CGM that does not require a prescription and can be worn for up to 15 days. The device is designed to help users understand how diet, exercise, stress, and sleep affect glucose levels. By tracking specific foods’ effects, Stelo offers a granular view that can be especially useful for those managing prediabetes or obesity.

Lingo’s Minute‑by‑Minute Updates Power Real‑Time Habit Change

The source notes that Lingo provides real‑time updates every minute, is discreet, water‑resistant, and lasts up to 14 days without charging. Its app delivers science‑backed tips to build healthier habits over time , making it attractive for users who want instant feedback on lifestyle tweaks.

Levels Combines CGM Data With Biomarker Testing for Deep Insight

Levels, as described, takes a broader approach by merging CGM data with lifestyle inputs and biomarker testing to identify patterns in glucose spikes,variability, and insulin sensitivity. users can bring their own CGM or obtain one through Levels, offering flexibility for those already invested in other devices.

Who Should Consider OTC CGMs and When to Seek Medical Advice?

The report stresses that while CGMs can help manage diabetes , delay complications, and save money, they should not replace medical guidance. Users are urged to consult healthcare professionals and diabetes educators to determine the right CGM system and learn how to interpret and use data effectively.

Open Question: How Will Insurance and Regulation Adapt to OTC CGMs?

One unanswered point is whether insurers will cover OTC CGMs or if new regulations will emerge to standardize data privacy and device accuracy. The source does not address these policy implications, leaving a gap in understanding the long‑term accessibility of these technologies.